<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H5305977883C8436D9C00330E6A024598" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5806 IH: 21st Century Tools for Pain and Addiction Treatment Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-05-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5806</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180515">May 15, 2018</action-date><action-desc><sponsor name-id="B001248">Mr. Burgess</sponsor> (for himself, <cosponsor name-id="B001275">Mr. Bucshon</cosponsor>, and <cosponsor name-id="G000568">Mr. Griffith</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Secretary of Health and Human Services to issue guidance with respect to the
			 expedited approval of certain drugs, and for other purposes.</official-title></form>
	<legis-body id="H2B343E49D28F49468A2761C3067C4DB9" style="OLC">
 <section id="H8AEC5BEDA0AC4CE691A67990D0E399FF" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>21st Century Tools for Pain and Addiction Treatment Act</short-title></quote>.</text> </section><section id="H8337A9798260427EB94CAAD40E98D04B"><enum>2.</enum><header>Clarifying FDA regulation of non-addictive pain and addiction therapies</header> <subsection id="H20BD5077BC4E4E74B91252FE00A14228"><enum>(a)</enum><header>Public meetings</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall hold not less than one public meeting to address the challenges and barriers of developing non-addictive medical products intended to treat pain or addiction, which may include—</text>
 <paragraph id="H63FAFD87D41248C7BF12A711271B7F45"><enum>(1)</enum><text display-inline="yes-display-inline">the application of novel clinical trial designs (consistent with section 3021 of the 21st Century Cures Act (<external-xref legal-doc="public-law" parsable-cite="pl/114/255">Public Law 114–255</external-xref>)), use of real world evidence (consistent with section 505F of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355g">21 U.S.C. 355g</external-xref>)), and use of patient experience data (consistent with section 569C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-8c">21 U.S.C. 360bbb–8c</external-xref>)) for the development of non-addictive medical products intended to treat pain or addiction; and</text>
 </paragraph><paragraph id="HB262835F0F2F493CB6D737985645A9DD"><enum>(2)</enum><text display-inline="yes-display-inline">the application of eligibility criteria under sections 506 and 515B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>, 360e–3) for non-addictive medical products intended to treat pain or addiction.</text>
 </paragraph></subsection><subsection id="HBE004C43BC4E4FB9815B575445CCE01B"><enum>(b)</enum><header>Guidance</header><text display-inline="yes-display-inline">Not later than one year after the public meetings are conducted under subsection (a) the Secretary shall issue one or more final guidance documents, or update existing guidance documents, to help address challenges to developing non-addictive medical products to treat pain or addiction. Such guidance documents shall include information regarding—</text>
 <paragraph id="H089C7AC407F04B57902C34D6815A0DB3"><enum>(1)</enum><text display-inline="yes-display-inline">how the Food and Drug Administration may apply sections 506 and 515B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>, 360e–3) to non-addictive medical products intended to treat pain or addiction, including the circumstances under which the Secretary—</text>
 <subparagraph id="H6A5E3D96E88E4D229236C067378BF337"><enum>(A)</enum><text display-inline="yes-display-inline">may apply the eligibility criteria under such sections 506 and 515B to non-opioid or non-addictive medical products intended to treat pain or addiction;</text>
 </subparagraph><subparagraph id="HDD3636E2D4014C7A9810C42462E91154"><enum>(B)</enum><text display-inline="yes-display-inline">considers the risk of addiction of controlled substances approved to treat pain when establishing unmet medical need; and</text>
 </subparagraph><subparagraph id="HCD1034E96E1C411385E9D4BCCC7B8E6B"><enum>(C)</enum><text display-inline="yes-display-inline">considers pain, pain control, or pain management in assessing whether a disease or condition is a serious or life-threatening disease or condition; and</text>
 </subparagraph></paragraph><paragraph id="HDAEE9C9DA45D475CA8C8C7DB70B8E1CF"><enum>(2)</enum><text display-inline="yes-display-inline">the methods by which sponsors may evaluate acute and chronic pain, endpoints for non-addictive medical products intended to treat pain, the manner in which endpoints and evaluations of efficacy will be applied across and within review divisions, taking into consideration the etiology of the underlying disease, and the manner in which sponsors may use surrogate endpoints, intermediate endpoints, and real world evidence.</text>
 </paragraph></subsection><subsection id="H2F8EB980FDA74B2B8F901C225AF985B3"><enum>(c)</enum><header>Medical product defined</header><text display-inline="yes-display-inline">In this section, the term <quote>medical product</quote> means a drug (as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(g)(1)</external-xref>)), biological product (as defined in section 351(i) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)</external-xref>)), or device (as defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(h)</external-xref>)).</text>
			</subsection></section></legis-body></bill>


